Skip to main content

Table 3 Demographic, clinical, and laboratory characteristics at renal biopsy and treatment

From: Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy

Total

Model 1

Model 2

Model 3

< 18.5

18.5–25

P value

18.5–25

25–28

P value

18.5–25

≥28

P value

No. of patients

295

37

37

 

48

48

 

12

12

 

Follow-up time

(months)

45.4 ± 26.6

36.3 ± 24.0

43.3 ± 23.6

0.158

41.5 ± 23.1

43.9 ± 34.3

0.682

40.4 ± 28.2

41.5 ± 21.6

0.810

eGFR

(ml/min per 1.73 m2)

88.82 ± 31.57

103.84 ± 34.25

99.83 ± 34.91

0.406

83.99 ± 33.18

83.75 ± 29.88

0.809

76.32 ± 41.11

87.41 ± 30.83

0.722

Proteinuria (g/24 h)

1.60 ± 8.78

0.60 ± 0.46

0.74 ± 0.69

0.567

0.84 ± 0.82

1.01 ± 0.85

0.105

1.22 ± 0.99

1.39 ± 1.43

0.786

Treatment

          

P

17

2

2

1

4

2

0.677

0

0

1

P + CTX

1

1

0

1

0

0

1

0

0

1

P + LEF

5

1

1

1

0

1

1

0

0

1

ACEI/ARB

70

10

8

0.787

8

14

0.224

3

2

1

P + ACEI/ARB

81

6

12

0.173

14

11

0.642

4

5

1

  1. Abbreviations: P prednisone; CTX cytoxan; LEF leflunomide; ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor antagonist
  2. Model 1, 2 and 3 were performed by propensity-score matching. The matching covariates were age, sex, eGFR and proteinuria. The control group were patients with normal weight (18.5 ≤ BMI<25 kg/m2), and the matching group were patients with low-weight (BMI<18.5 kg/m2), overweight (25 ≤ BMI<28 kg/m2) and obese (BMI ≥ 28 kg/m2)